BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9349517)

  • 1. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids.
    Schofield K; D'Aquila T; Rimm DL
    Cancer; 1997 Oct; 81(5):293-8. PubMed ID: 9349517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.
    Davidson B; Berner A; Nesland JM; Risberg B; Berner HS; Tropè CG; Kristensen GB; Bryne M; Ann Florenes V
    J Pathol; 2000 Dec; 192(4):460-9. PubMed ID: 11113863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
    Ko EC; Jhala NC; Shultz JJ; Chhieng DC
    Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
    Afify AM; Stern R; Michael CW
    Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells.
    Davidson B; Nielsen S; Christensen J; Asschenfeldt P; Berner A; Risberg B; Johansen P
    Am J Surg Pathol; 2001 Nov; 25(11):1405-12. PubMed ID: 11684957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of cell proliferation markers (Minichromosome maintenance protein 7, topoisomerase IIalpha and Ki-67) in cavital fluid cytology: can we differentiate reactive mesothelial cells from malignant cells?
    Kimura F; Kawamura J; Watanabe J; Kamoshida S; Kawai K; Okayasu I; Kuwao S
    Diagn Cytopathol; 2010 Mar; 38(3):161-7. PubMed ID: 19821496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.
    Ruitenbeek T; Gouw AS; Poppema S
    Arch Pathol Lab Med; 1994 Mar; 118(3):265-9. PubMed ID: 8135629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
    Su XY; Li GD; Liu HB; Jiang LL
    Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions.
    Betta PG; Pavesi M; Pastormerlo M; Tallarida F; Bellingeri D; Bocca R
    Pathologica; 1991; 83(1083):99-104. PubMed ID: 1866206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
    Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
    Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serous effusions in malignant lymphomas: a review.
    Das DK
    Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of BCA-225 in the cytologic diagnosis of malignant effusions: an immunocytochemical study of 197 cases.
    Loy TS; Diaz-Arias AA; Bickel JT
    Mod Pathol; 1990 May; 3(3):294-7. PubMed ID: 2194212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytological study of serous effusions with the aid of tumour markers.
    Ray K; Mittal S; Gupta H; Jain M
    J Indian Med Assoc; 1999 Jan; 97(1):11-2, 19. PubMed ID: 10549179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases.
    Davidson B; Dong HP; Berner A; Christensen J; Nielsen S; Johansen P; Bryne M; Asschenfeldt P; Risberg B
    Am J Clin Pathol; 2002 Jul; 118(1):85-92. PubMed ID: 12109861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
    Hasteh F; Lin GY; Weidner N; Michael CW
    Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new epithelial membrane antigen (Calam 27) as a marker of carcinoma in serous effusions.
    Gioanni J; Caldani C; Zanghellini E; Mazeau C; Duplay H; Ferrua B; Schneider M
    Acta Cytol; 1991; 35(3):315-9. PubMed ID: 2042433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.